YS Biopharma Co Ltd
NASDAQ:LSB
YS Biopharma Co Ltd
Research & Development
YS Biopharma Co Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
YS Biopharma Co Ltd
NASDAQ:LSB
|
Research & Development
-¥146.4m
|
CAGR 3-Years
12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Research & Development
-¥13.6B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Research & Development
-¥2.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
RemeGen Co Ltd
SSE:688331
|
Research & Development
-¥1.4B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Research & Development
-¥1.2B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Research & Development
-¥1.2B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
YS Biopharma Co Ltd
Glance View
YS Biopharma Co. Ltd. operates as a biopharmaceutical company, which is dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. The company is headquartered in Beijing, Beijing. The firm's vaccine product YSJATM rabies vaccine has been commercialized. The firm also has four product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 and PIKA YS-HBV-001, and four preclinical stage product candidates, targeting HBV, influenza and cancer with enormous medical demand. In addition, the Company is working on a series of therapeutic targets, rabies and products at the discovery stage.
See Also
What is YS Biopharma Co Ltd's Research & Development?
Research & Development
-146.4m
CNY
Based on the financial report for Mar 31, 2025, YS Biopharma Co Ltd's Research & Development amounts to -146.4m CNY.
What is YS Biopharma Co Ltd's Research & Development growth rate?
Research & Development CAGR 3Y
12%
Over the last year, the Research & Development growth was 52%. The average annual Research & Development growth rates for YS Biopharma Co Ltd have been 12% over the past three years .
